GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Biotechnology Corp (ROCO:3176) » Definitions » Other Operating Expense

Medigen Biotechnology (ROCO:3176) Other Operating Expense : NT$0 Mil (TTM As of Jun. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Medigen Biotechnology Other Operating Expense?

Medigen Biotechnology's Other Operating Expense for the three months ended in Jun. 2024 was NT$0 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2024 was NT$0 Mil.

Medigen Biotechnology's quarterly Other Operating Expense declined from Dec. 2023 (NT$0 Mil) to Mar. 2024 (NT$0 Mil) and declined from Mar. 2024 (NT$0 Mil) to Jun. 2024 (NT$0 Mil).

Medigen Biotechnology's annual Other Operating Expense increased from Dec. 2021 (NT$0 Mil) to Dec. 2022 (NT$0 Mil) but then stayed the same from Dec. 2022 (NT$0 Mil) to Dec. 2023 (NT$0 Mil).


Medigen Biotechnology Other Operating Expense Historical Data

The historical data trend for Medigen Biotechnology's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigen Biotechnology Other Operating Expense Chart

Medigen Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Medigen Biotechnology Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Medigen Biotechnology Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medigen Biotechnology Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Medigen Biotechnology's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Medigen Biotechnology Business Description

Traded in Other Exchanges
N/A
Address
Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560
Medigen Biotechnology Corp is a biopharmaceutical company engaged in new drug development, drug discovery, molecular diagnostics, vaccine, and generic drugs. The company has four segments: Nucleic acid department: segment, which derives maximum revenue, is responsible for services of testing reagents, instruments and inspection on behalf of others; New drug and vaccine research and development segment: responsible for the development and relevant services of new drugs and vaccine; Cytotherapy department: responsible for research and development and relevant services of cytotherapy; and Generic drug, aesthetic medicine product and dietary supplement segment is responsible for production and sales and relevant services of western medicine, aesthetic medicine product and dietary supplement.

Medigen Biotechnology Headlines

No Headlines